Cancer Immunology, Immunotherapy

, Volume 60, Issue 4, pp 467–477

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)

  • Anna Maria Di Giacomo
  • Riccardo Danielli
  • Luana Calabrò
  • Erica Bertocci
  • Chiara Nannicini
  • Diana Giannarelli
  • Angelo Balestrazzi
  • Francesco Vigni
  • Valentina Riversi
  • Clelia Miracco
  • Maurizio Biagioli
  • Maresa Altomonte
  • Michele Maio
Original Article

DOI: 10.1007/s00262-010-0958-2

Cite this article as:
Di Giacomo, A.M., Danielli, R., Calabrò, L. et al. Cancer Immunol Immunother (2011) 60: 467. doi:10.1007/s00262-010-0958-2

Abstract

Aim of study

To evaluate the feasibility of ipilimumab treatment for metastatic melanoma outside the boundaries of clinical trials, in a setting similar to that of daily practice.

Methods

Ipilimumab was available upon physician request in the Expanded Access Programme for patients with life-threatening, unresectable stage III/IV melanoma who failed or did not tolerate previous treatments and for whom no therapeutic option was available. Induction treatment with ipilimumab 10 mg/kg was administered intravenously every 3 weeks, for a total of 4 doses, with maintenance doses every 12 weeks based on physicians’ discretion and clinical judgment. Tumors were assessed at baseline, Week 12, and every 12 weeks thereafter per mWHO response criteria, and clinical response was scored as complete response (CR), partial response (PR), stable disease (SD), or progressive disease. Durable disease control (DC) was defined as SD at least 24 weeks from the first dose, CR, or PR.

Results

Disease control rate at 24 and 60 weeks was 29.6% and 15%, respectively. Median overall survival at a median follow-up of 8.5 months was 9 months. The 1- and 2-year survival rates were 34.8% and 23.5%, respectively. Changes in lymphocyte count slope and absolute number during ipilimumab treatment appear to correlate with clinical response and survival, respectively. Adverse events were predominantly immune related, manageable, and generally reversible. One patient died from pancytopenia, considered possibly treatment related.

Conclusion

Ipilimumab was a feasible treatment for malignant melanoma in heavily pretreated, progressing patients. A sizeable proportion of patients experienced durable DC, including benefits to long-term survival.

Keywords

Ipilimumab Cytotoxic T-lymphocyte antigen 4 Advanced melanoma Immunotherapy Compassionate use Monoclonal antibody 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Anna Maria Di Giacomo
    • 1
  • Riccardo Danielli
    • 1
  • Luana Calabrò
    • 1
  • Erica Bertocci
    • 1
  • Chiara Nannicini
    • 1
  • Diana Giannarelli
    • 2
  • Angelo Balestrazzi
    • 3
  • Francesco Vigni
    • 4
  • Valentina Riversi
    • 4
  • Clelia Miracco
    • 5
  • Maurizio Biagioli
    • 6
  • Maresa Altomonte
    • 1
  • Michele Maio
    • 1
    • 7
  1. 1.Medical Oncology and ImmunotherapyUniversity Hospital of Siena, Istituto Toscano TumoriSienaItaly
  2. 2.Statistical UnitRegina Elena Cancer InstituteRomeItaly
  3. 3.Ophthalmology, University Hospital of Siena, Istituto Toscano TumoriSienaItaly
  4. 4.Radiology, University Hospital of Siena, Istituto Toscano TumoriSienaItaly
  5. 5.Pathology, University Hospital of Siena, Istituto Toscano TumoriSienaItaly
  6. 6.Dermatology, University Hospital of Siena, Istituto Toscano TumoriSienaItaly
  7. 7.Cancer Bioimmunotherapy UnitCentro di Riferimento OncologicoAvianoItaly

Personalised recommendations